Key result
Ultrathin bioresorbable polymer sirolimus-eluting stents cut 2-year TLF ~37% vs durable polymer everolimus-eluting stents.
Why the study?
Whether newer stent developments such as bioresorbable polymers, altered architecture, and new metal alloys improve long-term clinical safety and efficacy has been inconsistent in prior studies.
Does an ultrathin bioresorbable polymer sirolimus-eluting stent improve clinical outcomes compared to a thin durable polymer everolimus-eluting stent in patients undergoing coronary revascularization?
RCT (n=1,334)
randomized
Yes
Does an ultrathin bioresorbable polymer sirolimus-eluting stent improve clinical outcomes compared to a thin durable polymer everolimus-eluting stent in patients undergoing coronary revascularization?
Ultrathin bioresorbable polymer sirolimus-eluting stents significantly reduced 2-year target lesion failure and target vessel MI compared to thin durable polymer everolimus-eluting stents.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“To our knowledge, this is the only trial that has demonstrated superiority [of a new stent] to the Xience drug-eluting stent in a large, randomized trial. This is a landmark in interventional cardiology that raises the bar for future comparisons”
“This is the first head-to-head, randomized comparison trial to show superiority over the Xience stent, which has been the benchmark for comparisons not only of novel drug-eluting stents, but also bioresorbable stents as well”
“Differences in endpoints that are observed, and the timing of them, seem to vary across both the individual trials and the meta-analyses, but the theme that is emerging is one of superior benefit with ultrathin-strut drug-eluting stents”
Supports the safety of ultrathin strut bioresorbable polymer stents in routine practice.
BACKGROUND: Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture, and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies. OBJECTIVES: The authors sought to compare late-term clinical outcomes among patients treated with an ultrathin strut (60 μm) bioresorbable polymer sirolimus-eluting stent (BP SES) and a thin strut (81 μm) durable polymer everolimus-eluting stent (DP EES) in a large randomized trial. METHODS: BIOFLOW V (Biotronik Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects with Up to Three De Novo or Restenotic Coronary Artery Lesions V) was an international randomized trial comparing coronary revascularization with BP SES and DP EES regarding the primary endpoint of 12-month target lesion failure (TLF). Analysis of pre-specified 2-year clinical outcomes was performed. RESULTS: Among 1,334 patients randomized to treatment with BP SES (n = 884) or DP EES (n = 450), the 2-year TLF rate was 7.5% for BP SES and 11.9% for DP EES (-4.33% treatment difference; 95% confidence interval: -8.16% to -0.91%; p = 0.015), driven by differences in target vessel myocardial infarction (MI) (5.3% vs. 9.5%; p = 0.01) and ischemia-driven target lesion revascularization (2.6% vs. 4.9%; p = 0.04). Rates of cardiac death or MI were 7.0% versus 10.4% for BP SES and DP EES, respectively (p = 0.047). Late/very late definite stent thrombosis was statistically lower for BP SES compared with DP EES (0.1% vs. 1.0%; p = 0.045). CONCLUSIONS: In a large randomized trial, significant differences in both TLF and target vessel-related MI persisted through 2 years, favoring treatment with BP SES over DP EES. Significantly lower cumulative target lesion revascularization and late/very late stent thrombosis were also observed with BP SES. (Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions [BIOFLOW-V]; NCT02389946).
No takes yet. Share an insight, caveat, or question.
Kandzari et al. (2018) conducted an RCT in Coronary Artery Lesions (n=1,334). Ultrathin bioresorbable polymer sirolimus-eluting stent (BP SES) vs. Thin durable polymer everolimus-eluting stent (DP EES) was evaluated on 2-year target lesion failure (TLF) (treatment difference -4.33%, 95% CI -8.16 to -0.91, p=0.015). Ultrathin bioresorbable polymer sirolimus-eluting stents reduced 2-year target lesion failure compared to durable polymer everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: